Chelated Drug Delivery for Neural Prostheses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering minocycline to neural prostheses face challenges in achieving high local concentrations for neuroprotection and preventing inflammation, as systemic administration is ineffective and local delivery systems like solid macroparticles or nanoparticles have limitations such as low entrapment efficiency and potential for inflammation due to acidic degradation products.
Innovation Solution
A composition comprising a therapeutic agent, a polyelectrolyte, and a polyvalent metal ion, where the therapeutic agent chelates with the metal ion, forming complexes with dextran sulfate and divalent metal ions like Ca2+ or Mg2+, which are used to create biocompatible hydrogels or layer-by-layer assemblies for sustained release and reduced inflammation around neural prostheses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If minocycline is administered systemically, then it can treat inflammation and infection, but it cannot achieve sufficiently high local concentration at the implant site for neuroprotection
Solution Approach 1:
The patent applies local quality by transitioning from systemic administration to local delivery at the implant site. Minocycline is incorporated into coatings or matrices that are directly applied to the neural prosthesis surface, ensuring high local concentration precisely where neuroprotection is needed, rather than distributing the drug systemically throughout the body.
Solution Approach 2:
The patent uses biocompatible materials such as polymers, hydrogels, or nanoparticles as intermediaries to deliver minocycline locally. These materials serve as carriers that can be applied to the implant surface and provide controlled release of the antibiotic, acting as a mediator between the drug and the target tissue.
2Quantity of substance
If solid macroparticles or nanoparticles are used for local delivery, then high local concentration can be achieved, but entrapment efficiency is low and acidic degradation products cause inflammation
Solution Approach 1:
The patent applies parameter changes by modifying the chemical composition and degradation characteristics of the delivery matrix. Instead of using materials that degrade into acidic products, the invention employs biocompatible polymers and hydrogels with neutral or buffered degradation profiles, changing the chemical parameters of the delivery system to eliminate harmful effects while maintaining effective drug delivery.
Solution Approach 2:
The patent uses composite materials combining minocycline with biocompatible polymers, hydrogels, or nanoparticle matrices. These composite structures provide both the mechanical support needed for implant coatings and the controlled release properties required for sustained local delivery, while the biocompatible composition avoids inflammatory responses.
3Quantity of substance
If minocycline is released rapidly, then high initial concentration is achieved, but the duration of neuroprotection is insufficient
Solution Approach 1:
The patent applies periodic action through controlled release mechanisms that deliver minocycline in sustained intervals. The coating or matrix is designed to release the antibiotic over an extended period, providing periodic dosing that maintains therapeutic levels continuously rather than as a single rapid dose, thereby extending the duration of neuroprotection.
Solution Approach 2:
The patent achieves continuity of useful action by designing delivery systems that provide sustained, continuous release of minocycline from the implant coating or matrix. This ensures uninterrupted neuroprotection and anti-inflammatory coverage throughout the critical period following implantation, rather than allowing drug levels to drop after an initial burst.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables sustained and controlled release of minocycline, maintaining anti-inflammatory properties and reducing cytotoxicity, thereby improving the longevity and performance of neural prostheses by minimizing inflammation and infection.
Implementation Method 1
the therapeutic agent chelates at least a fraction of the polyvalent metal ion
Implementation Method 2
the polyelectrolyte comprises a polyanion, a predominantly polyanionic polyampholyte, or any combinations thereof
Data Source
AI summary
The present invention provides drug delivery compositions that allow for immediate and/or sustained release of a therapeutic agent contained within the system. The present invention also provides drug delivery compositions that preserve the stability of the therapeutic agent contained within during the sustained release. The present invention further provides a method of treating, ameliorating, or preventing an inflammation-related disease or disorder in a subject using the compositions of the invention.